Impact of extended-release dalfampridine on walking ability in patients with multiple sclerosis

Hayes KC. Neuropsychiatr Dis Treat. 2011;7:229-39.

A good summary of Dalfampridine (formerly fampridine) use in MS.

Click here to download PDF of article.

“It is a great pity we don’t have access to this drug; several of my patients may benefit from its use.”

COI: I have received a one-off consultancy payment from Biogen-Idec in relation to EMA’s negative decision concerning the licensing of Dalfampridine in Europe.

Leave a Reply

%d bloggers like this: